An 8-gene assay which can non-invasively identify patients suffering from antibody-mediated rejection of kidney transplant has recently been discovered in a research study led by scientists at KU ...

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will ...

"This IND for CID-103 is a significant milestone in our mission at CASI to develop innovative therapies for patients with organ transplant rejection and autoimmune diseases," said David Cory, CEO of ...

An investigational monoclonal antibody appeared to have therapeutic benefits among kidney transplant patients with antibody-mediated rejection, a randomized phase II trial showed. After 24 weeks ...

Akifova A, Budde K, Amann K, et al. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial. Nephrol Dial Transplant.

Reducing De Novo Donor-Specific Antibody Levels During Acute Rejection Diminishes Renal Allograft Loss Everly MJ, Everly JJ, Arend LJ, et al Am J Transplant. 2009;9:1063-1071 ...

After week 24, greater resolution of morphologic antibody-mediated rejection was observed at kidney biopsy in the felzartamab than placebo group: 82% vs 20%. The felzartamab arm had a 77% decrease ...

Antibody-mediated rejection (AMR) is a critical barrier to long-term allograft survival in organ transplantation. This complex immunological phenomenon occurs when recipient-derived antibodies ...

At week 24, resolution of morphologic antibody-mediated rejection was more frequent with felzartamab (in 9 of 11 patients [82%]) than with placebo (in 2 of 10 patients [20%]), for a difference of ...